Oracle Announces Oncology EHR With Embedded AI for Cancer Care

Oracle announced Oracle Health Oncology EHR on September 23, 2026, at the Oracle Health and Life Sciences Summit in Orlando, Florida, introducing an electronic health record purpose-built for cancer care with embedded AI agents and clinical decision support.

The solution builds on Oracle’s AI-powered ambulatory EHR, and Oracle said it is expected to empower care teams with AI-driven workflows, insights, and connected patient information aimed at more effective, personalized treatment. It brings together oncology-specific workflows, clinical intelligence derived from multiple data sources, and connected information intended to support patient care from diagnosis through treatment and follow-up.

Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, pointed to fragmented information, a lack of clinical insights, and antiquated technology that forces patients to search for and recount their history repeatedly, risking critical missed details. She said the oncology EHR is “designed to bring the patient’s story together and provide personalized treatment recommendations,” helping clinicians focus their time and expertise on the person in front of them.

Coordinating the Complexity of Cancer Care

Oracle describes cancer care as among the most complex forms of medicine, with multidisciplinary treatment requiring oncologists and their teams to coordinate rapidly changing treatment plans, chemotherapy regimens, laboratory and imaging results, medications, referrals, and insurance requirements across multiple care settings. When that information is fragmented, clinicians lose valuable time assembling the context needed to make decisions, while patients face a disconnected care experience.

With embedded AI agents and clinical decision support built in, Oracle said the context-aware EHR is expected to help care teams manage that complexity through an intuitive and responsive experience across inpatient and outpatient settings.

Oracle Health’s AI-powered assistant for oncologists is expected to connect results, decision support, and action across the cancer care journey. According to Oracle, planned functions range from patient snapshots and pre-visit summaries that surface what has changed to specialized assistants for Tumor Board preparation and guideline-grounded treatment planning, and the assistant can carry clinicians’ decisions into workflows such as orders, referrals, documentation, and coding.

Oracle also described a broader vision of a connected ecosystem of role-based AI assistants supporting nurses, patients, care coordinators, researchers, and the wider multidisciplinary cancer care team, working together with shared context throughout the patient journey.

Four Planned Capability Groups

Oracle outlined four groups of planned capabilities, each framed as intended functionality rather than currently available features. Unified cancer-care timelines are intended to give users a clear, chronological view of cancer-related diagnoses and treatments, supporting continuity of care and informed decision-making. Connected worklists for nurse navigators are intended to support care coordination from clinician diagnosis through treatment and survivorship, helping navigators maintain holistic, connected care plans.

Intelligent precision oncology insights are intended to unify genomic, radiology, pathology, laboratory, pharmacy, and social determinants of health data to support diagnoses and evidence-based treatment decisions. Oracle said this group also establishes a foundation for future capabilities such as pathway guidance, predictive analytics, trial matching, cost comparisons, and industry content.

Streamlined regimen planning workflows are intended to simplify chemotherapy and immunotherapy ordering, with lifetime cumulative-dose calculations, mobile ordering, response-to-treatment documentation, and simplified regimen maintenance. Oracle said the workflows are meant to help care teams manage treatment changes and support consistent, evidence-based care.

General Product Direction

Oracle presented the oncology EHR’s capabilities as planned and expected rather than currently available. The Future Product Disclaimer attached to the announcement states that the outline reflects general product direction, is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and the development, release, timing, and pricing of any described features may change at Oracle’s sole discretion.

The oncology EHR extends Oracle’s newer ambulatory product line. According to Oracle Health’s what’s-new index, Oracle introduced its next-generation AI-powered EHR on August 13, 2025, and that EHR achieved ONC certification and readiness for adoption by U.S. ambulatory customers on November 18, 2025. Oracle describes the certified EHR as built on a secure, modern cloud architecture with AI embedded in every layer and workflow.